Background: Chordoma is a rare bone cancer with limited treatment options. Clinical trials are crucial for developing effective therapies, but their success depends on including diverse patient populations. The objective of this study was to systematically evaluate the reporting of racial, ethnic, and socioeconomic diversity in United States clinical trials exploring treatment for chordoma.
Methods: A literature search was conducted through PubMed/Medline, Cochrane, Epistemonikos, and ClinicalTrials.gov databases for published US chordoma trials up until 19 August 2024. The data collected included trial characteristics and racial and ethnic data, as well as socioeconomic indicators when available. Methodological Index for Non-Randomized Studies (MINORS) and Revised Cochrane Risk-of-Bias Tool for Randomized Trials (RoB2) analyses were adopted to assess the methodological quality. The N-1 Chi-squared (χ) test was implemented to compare the reported racial and ethnic data with the most recent US Census Bureau data.
Results: Five trials involving 111 patients (median age: 63 years; 34% female) were included. Four studies (80%) were single-arm non-randomized studies with one study (25%) having a high methodological quality and three (75%) having a moderate quality based on the MINORS analysis. Most patients (91%, = 82) were White/Caucasian, representing a proportion which was significantly higher than the reported 75% in the US population ( = 0.0005). Black/African American patients (2%, = 2) were significantly underrepresented compared to the 14% in the US population ( = 0.0015). Regarding ethnicity, Hispanic/Latino patients (7%, = 6) were significantly underrepresented compared to the 20% in the US population ( = 0.0021). No measures of socioeconomic status were reported.
Conclusions: This systematic review highlighted the need for improved racial and ethnic diversity in chordoma trials and the better reporting of socioeconomic data. The underrepresentation of minority groups may obscure potential disparities in disease incidence, treatment access, and clinical outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3390/cancers17020225 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Determinants of dementia diagnosis in U.S. primary care in the past decade: A scoping review.
J Prev Alzheimers Dis
February 2025
Department of Health Behavior and Health Equity, University of Michigan School of Public Health, 1415 Washington Heights, Ann Arbor, MI 48109-2029, United States.
Background: Alzheimer's disease and related dementias (ADRD) are chronically underdiagnosed in the U.S., particularly among minoritized racial and ethnic groups.
View Article and Find Full Text PDFRacial and ethnic enrollment disparities in clinical trials leading to FDA approvals for gynecologic malignancies.
Am J Obstet Gynecol
January 2025
Division of Gynecologic Oncology, Mount Sinai Medical Center, Miami Beach, Florida, USA.
Background: Black women and other minorities have higher age adjusted incidence risk for cervical and endometrial cancer than White women. However, the extent of racial and ethnic disparities in clinical trial enrollment among studies performed mainly in North America and Europe for gynecologic malignancy is unknown.
Objective: This study analyzed enrollment rates by race/ethnicity in trials that led to Food and Drug Administration (FDA) approvals for gynecological cancers from 2010 to 2024.
Racial and ethnic disparities in post-acute care service utilization after stroke.
Geriatr Nurs
January 2025
Center for Health Policy, Columbia University School of Nursing, 560 West 168 Street, New York, NY 10032, USA.
Evidence examining disparities in post-acute care (PAC) utilization among various racial and ethnic groups after stroke and the influence of social determinants of health (SDOH) in these decisions is lacking. Thus, we searched the literature from January 2000 to November 2023 regarding PAC among individuals after stroke through: 1) Pubmed, 2) Scopus, 3) Web of Science, 4) Embase, and 5) CINAHL. We found 14 studies.
View Article and Find Full Text PDFUrinary Fluoride Levels Among Youth in the National Health and Nutrition Examination Survey (NHANES) 2015-2016: Potential Differences According to Race.
Nutrients
January 2025
College of Public Health and Health Professions, University of Florida, Gainesville, FL 32611, USA.
Background/objectives: Urinary fluoride (UF) is the most well-established biomarker for fluoride exposure, and understanding its distribution can inform risk assessment for potential adverse systemic health effects. To our knowledge, this study is the first to report distributions of UF among youth according to sociodemographic factors in a nationally representative United States (US) sample.
Methods: The study included 1191 children aged 6-11 years and 1217 adolescents aged 12-19 years from the National Health and Nutrition Examination Survey (NHANES) 2015-2016.
Diet Quality, Metabolic Syndrome, and Nativity Status: Elucidating Metabolic Advantage and Disadvantage Among Non-US-Native and US-Native Populations Using NHANES Data (2013-2018).
Nutrients
January 2025
Office of Minority Health and Health Disparities Research, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, 1010 New Jersey Ave. SE, Washington, DC 20003, USA.
Background/objectives: Nutrient-poor diet quality is a major driver of the global burden of metabolic syndrome (MetS). The US ranks among the lowest in diet quality and has the highest rate of immigration, which may present unique challenges for non-US-native populations who experience changes in access to health-promoting resources. This study examined associations among MetS, nativity status, diet quality, and interaction effects of race-ethnicity among Hispanic, Asian, Black, and White US-native and non-US-native adults.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!